Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Münster
Clinical trial register · Germany

Clinical Trials in Münster, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5060 matching records held by the registry are in this view. Synced 14 Oct 2026, 03:18 UTC
5060
Studies in scope
all four open statuses
2879
Recruiting now
open to new participants
987
Lead sponsors
across recruiting studies
Top sites
Berlin 1589 Hamburg 891 Essen 764 Dresden 713 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital Muenster16 Universität Münster14 AstraZeneca13 Merck Sharp & Dohme LLC12 AbbVie12
Site location
Berlin1589 Hamburg891 Essen764 Dresden713 Heidelberg627
All 640 locations
Target enrolment
to

Trials with a site in Münster

353 of 5060 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Berlin, Hanover, Münster, Cologne, Homburg, Leipzig, Kiel, Essen
2027-11-23
Not yet open
Takeda
Phase 2
36
Bochum, Essen, München, Münster
2026-10-15
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Cologne, Leipzig, Münster
2026-09-29
Not yet open
Atrial Fibrillation Network
Not applicable
956
Cologne, Frankfurt, Hamburg, Münster
2026-09-01
Not yet open
Perioperative Role Of Vascular Endothelial Growth Factor In Cardiac Surgery-associated Acute Kidney Injury
NCT07803328Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury
Universität Münster
Observational
220
Münster
2026-09-01
Not yet open
Study of Serine Supplementation to Protect Vision in MacTel
NCT07342439Macular Telangiectasia Type 2 (MacTel)
The Lowy Medical Research Institute Limited
Phase 3
120
Bonn, Freiburg im Breisgau, Münster
2026-09
Recruiting
VectivBio AG
Phase 3
124
Heidelberg, Erlangen, Hamburg, Bonn, Essen, Münster, Aachen, Berlin
2026-08
Recruiting
Boehringer Ingelheim
Phase 3
448
Bad Bramstedt, Berlin, Dresden, Freiburg im Breisgau, Hanover, Heidelberg, Lübeck, Münster
2026-07-27
Recruiting
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
NCT07600476Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
Kupando GmbH
Phase 1
21
Munich, Würzburg, Münster
2026-07-03
Recruiting
Prilenia
Phase 3
400
Aachen, Bochum, Erlangen, Münster, Taufkirchen, Ulm
2026-07-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Münster, Hamburg
2026-06-18
Active, closed
AstraZeneca
Phase 2
326
Berlin, Cologne, Essen, Hamburg, Heidelberg, Homburg, München, Münster
2026-06-11
Recruiting
Insel Gruppe AG, University Hospital Bern
Not applicable
170
Münster, Ulm
2026-06-01
Recruiting
University Hospital Muenster
Not applicable
30
Münster
2026-06
Not yet open
Universität Münster
Not applicable
100
Münster
2026-06
Recruiting
OD-OS MacuTherm GmbH
Not applicable
240
Detmold, Hanover, Lübeck, Mannheim, Münster, Potsdam, Schleswig, Trier
2026-05-29
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Berlin, München, Münster
2026-05-28
Recruiting
Pfizer
Phase 2
24
Münster, Leipzig, Tübingen, Wuppertal
2026-05-28
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Bad Bentheim, Dresden, Frankfurt, Hamburg, Lübeck, Münster, Witten
2026-05-28
Recruiting
Takeda
Phase 3
300
Bayreuth, Münster, Halle, Berlin
2026-05-21
Recruiting
Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury
NCT07464431Acute Kidney Injury, Metabolic Acidosis, Critical Illness
DrugSodium Bicarbonate
Universität Münster
Phase 4
660
Münster
2026-05-07
Recruiting
Novo Nordisk A/S
Phase 3
300
Bochum, Hamburg, Hanover, Karlsruhe, Münster, Schleswig
2026-05-05
Recruiting
Novo Nordisk A/S
Phase 3
300
Bochum, Hamburg, Hanover, Karlsruhe, Münster, Schleswig
2026-05-05
Active, closed
Novo Nordisk A/S
Phase 3
606
Speyer, Hamburg, Leipzig, Lingen, Münster, Oldenburg in Holstein, Saint Ingbert-Oberwürzbach
2026-04-21
Recruiting
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
NCT07585890End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
University Medical Center Groningen
Observational
10,000
Aachen, Bonn, Essen, Frankfurt, Heidelberg, Kiel, Magdeburg, Münster
2026-04-21
Not yet open
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
20
Heidelberg, Düsseldorf, Essen, Münster, Berlin
2026-04
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Hamburg, Münster
2026-03-27
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Aachen, Bochum, Münster, Tübingen, Ulm
2026-03-24
Recruiting
University Hospital, Essen
Observational
180
Berlin, Bochum, Essen, Hamburg, Heidelberg, Münster
2026-03-18
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Berlin, Essen, Frankfurt, Freiburg im Breisgau, Hamburg, Hanover, Münster, Tübingen
2026-03-17
Recruiting
Hoffmann-La Roche
Phase 2
100
Freiburg im Breisgau, Hamburg, Münster, Nürtingen
2026-03-11
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Munich, Bad Bentheim, Bielefeld, Hamburg, Hanover, Lübeck, Münster, Tübingen
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Ludwigshafen, Bonn, Münster, Tübingen
2026-03-09
Recruiting
Priv.-Doz. Dr. med. Philipp Lenz
Not applicable
125
Münster
2026-03
Recruiting
University Hospital Muenster
Not applicable
84
Münster
2026-02-23
Recruiting
Universität Münster
Phase 2
30
Essen, Münster
2026-02-20
Recruiting
AstraZeneca
Phase 2
124
Aachen, Essen, Frankfurt, Greifswald, Heidelberg, Kiel, Leipzig, Münster
2026-02-10
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
Berlin, Heidelberg, Münster
2026-02-03
Recruiting
BeOne Medicines
Phase 3
500
Deggendorf, Frankfurt am Main, Münster, Straubing
2026-01-22
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Berlin, Bramsche, München, Münster
2026-01-20
Recruiting
Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices
NCT07273903CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Heinrich-Heine University, Duesseldorf
Observational
35
Düsseldorf, Münster
2026-01-15
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Heidelberg, Munich, Münster, Würzburg
2026-01-09
Recruiting
Amicus Therapeutics
Phase 3
8
Münster
2026-01-08
Recruiting
Norgine
Phase 3
212
Regensburg, Münster, Wuppertal, Mainz, Berlin
2025-12-29
Recruiting
Eli Lilly and Company
Phase 3
1,035
Berlin, Bünde, Essen, Hamburg, Münster, Oldenburg
2025-12-15
Recruiting
Takeda
Phase 3
110
Bad Bentheim, Cologne, Münster, Bonn, Mainz
2025-12-04
Recruiting
Bristol-Myers Squibb
Phase 3
366
Münster, Mainz, Berlin, Dresden, Erlangen
2025-12-03
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Bonn, Jena, Mainz, München, Münster
2025-12-02
Active, closed
IMPULS-NRW: Telemedicine in Specialized Outpatient Palliative Care
NCT07491679End of Life, Palliative Patients, Outpatient Treatment
University Hospital Muenster
Observational
150
Münster
2025-12-01
Recruiting
Women's Cancer Study Group GmbH
Phase 3
250
Cologne, Essen, Mönchengladbach, Münster, Frankfurt, Hamburg, Hildesheim, München
2025-11-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Stuttgart, Tübingen, Göttingen, Schwerin, Herne, Münster, Dresden, Erfurt
2025-11-26
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
München, Münster, Oldenburg, Regensburg, Würzburg
2025-11-24
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
München, Bad Bentheim, Frankfurt, Mainz, Münster
2025-11-24
Recruiting
Incyte Corporation
Phase 3
250
Berlin, Erlangen, Hamburg, Kiel, Leipzig, Mainz, München, Münster
2025-11-13
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Bonn, Sulzbach, Cologne, Giessen, Mainz, München, Münster, Tübingen
2025-11-10
Recruiting
Sanofi
Phase 2
208
Bochum, Bramsche, Frankfurt, Kiel, Mainz, Münster, Würzburg
2025-11-06
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Sankt Augustin, Heidelberg, Münster
2025-11-03
Recruiting
Pfizer
Phase 2
200
Stuttgart, Münster, Berlin, Dresden, Leipzig, Wuppertal
2025-10-30
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
Mainz, Münster
2025-10-20
Recruiting
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2025-10-01
Recruiting
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2025-10-01
Not yet open
Medical University Innsbruck
Not applicable
80
Berlin, Freiburg im Breisgau, Göttingen, München, Münster, Tübingen
2025-09-30
Recruiting
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
200
Dresden, Düsseldorf, Kassel, Marburg, München, Münster
2025-09-30
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Freiburg im Breisgau, Langenau, Mahlow, Hamburg, Bad Bentheim, Münster, Mainz, Quedlinburg
2025-09-22
Recruiting
GEL & MEDication Dysphagia
NCT07254663Neurological Diseases or Conditions, Healthy Participants
Heinrich-Heine University, Duesseldorf
Observational
500
Düsseldorf, Münster, Onsabrück
2025-09-15
Recruiting
European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™
NCT07668687Dissection of Thoracic Aorta, Dissection of Thoracic Descending Aorta, Aneurysm of Aorta, Thoracic, Penetrating Aortic Ulcers (PAUs)
Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd
Observational
100
Hamburg, Münster
2025-09-12
Recruiting
LEO Pharma
Phase 2
135
Bad Bentheim, Dresden, Göttingen, Hamburg, Kiel, Lübeck, Manheim, Münster
2025-09-11
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
400
Dresden, Münster
2025-08-08
Recruiting
Miltenyi Biomedicine GmbH
Phase 2
31
Münster
2025-08-04
Recruiting
Celgene
Phase 3
400
Ulm, Augsburg, Göttingen, Dortmund, Düsseldorf, Münster, Homburg, Erfurt
2025-07-28
Recruiting
AbbVie
Phase 3
120
Cottbus, Kassel, Münster
2025-07-28
Recruiting
Pfizer
Phase 3
150
Münster, Dresden
2025-07-24
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Bad Bentheim, Berlin, Göttingen, Heidelberg, Münster
2025-07-15
Recruiting
Bristol-Myers Squibb
Phase 3
586
Mannheim, Münster, Mainz, Berlin, Aachen, Bremen, Hamburg, Munich
2025-07-14
Active, closed
Glycomine, Inc.
Phase 2/3
50
Münster
2025-07-09
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Berlin, Bochum, Erbach im Odenwald, Essen, Greifswald, Heidelberg, Münster, Ulm
2025-06-23
Active, closed
NeVa Retrospective Comparative SR Study
NCT06964724Stroke Acute
Vesalio
Observational
800
Münster
2025-06-15
Recruiting
Boehringer Ingelheim
Phase 2
300
Dresden, Düsseldorf, Leipzig, Mannheim, Münster
2025-06-05
Recruiting
Celgene
Phase 2
200
Würzburg, Kassel, Bochum, Münster, Siegen, Meisenheim, Jena, Bielefeld
2025-06-05
Recruiting
GlaxoSmithKline
Phase 2
80
Münster, Dresden, Leipzig
2025-06-05
Recruiting
Charite University, Berlin, Germany
Not applicable
186
Hamburg, Aachen, Bonn, Münster, Berlin, Hanover, München, Regensburg
2025-06-02
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Tübingen, Cologne, Münster
2025-05-26
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Berlin, Erlangen, Lübeck, Mainz Am Rhein, Münster
2025-05-19
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Frankfurt am Main, Mainz, Bad Bentheim, Dresden, Hamburg, Heidelberg, Magdeburg, Münster
2025-05-16
Active, closed
Zura Bio Inc
Phase 2
225
Bad Bentheim, Bochum, Darmstadt, Dresden, Hamburg, Heidelberg, München, Münster
2025-05-16
Recruiting
Video-Tumorboard PLUS
NCT06980740Malignant Melanoma, Telemedicine
University Hospital Muenster
Observational
300
Bonn, Dresden, Münster
2025-05-01
Recruiting
University Hospital Muenster
Observational
100
Münster
2025-05-01
Recruiting
University Hospital Muenster
Observational
128
Münster
2025-05-01
Active, closed
Eli Lilly and Company
Phase 3
905
Bad Mergentheim, Bochum, Essen, Hamburg, Karlsburg, Leipzig, Münster, Oldenburg
2025-04-25
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Göttingen, Münster, Tübingen
2025-04-01
Recruiting
Universität Münster
Phase 3
1,022
Berlin, Bonn, Mainz, Münster
2025-03-31
Recruiting
Eli Lilly and Company
Phase 2
200
Essen, Leipzig, Münster, Oldenburg
2025-03-28
Active, closed
Hoffmann-La Roche
Phase 4
274
Frankfurt, Hanover, Münster, Ulm, Würzburg
2025-03-14
Active, closed
Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI
NCT06811805AKI - Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury
CardioRenal Systems, Inc.
Not applicable
300
Munich, Münster
2025-02-23
Active, closed
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
NCT06507865Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm
W.L.Gore & Associates
Observational
155
Hamburg, Heidelberg, Kiel, Münster
2025-02-20
Active, closed
Sanofi
Phase 3
231
Berlin, Frankfurt, Hamburg, Landsberg, Münster, Tübingen, Wiesbaden, Würzburg
2025-02-12
Recruiting
Dr. Inge Winter
Phase 3
418
Bielefeld, Dortmund, Frankfurt am Main, Mainz, Münster
2025-02-11
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Frankfurt am Main, Gummersbach, Hamburg, Münster
2025-02-07
Recruiting
LEOPARD Training and Validation Data Collection Study
NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
Assistance Publique - Hôpitaux de Paris
Observational
4,500
Aachen, Berlin, Hanover, Jena, Kiel, Leipzig, Münster, Tübingen
2025-02-04
Active, closed
argenx
Phase 3
154
Essen, Göttingen, Lübeck, Münster, Potsdam, Würzburg
2024-12-18
Active, closed
H. Lundbeck A/S
Phase 3
401
Beelitz-Heilstätten, Erlangen, Haag in Oberbayern, München, Münster, Tübingen
2024-12-03
Active, closed
GlaxoSmithKline
Phase 2
283
Berlin, Hanover, Münster
2024-11-11
Recruiting
Universität Münster
Observational
30
Münster
2024-11-06
Recruiting
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
NCT06675617Type B Aortic Dissection
Intressa Vascular SA
Not applicable
72
Düsseldorf, Frankfurt, Kiel, Leipzig, München, Münster
2024-10-30
Recruiting
Pfizer
Phase 3
900
Nürtingen, Tübingen, Münster, Hamburg
2024-10-22
Active, closed
Pfizer
Phase 3
600
Nürtingen, Tübingen, Mettmann, Münster, Hamburg
2024-10-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Heidelberg, Stuttgart, Kempten (Allgäu), Giessen, Oldenburg, Eschweiler, Münster, Mainz
2024-10-21
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Mannheim, Munich, Würzburg, Rostock, Berlin, Hanover, Lübeck, Münster
2024-10-17
Recruiting
Alnylam Pharmaceuticals
Phase 1
66
Berlin, Bochum, Bonn, Dresden, Münster, Taufkirchen, Ulm
2024-10-14
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
349
Beelitz, Dresden, Düsseldorf, Kassel, Leipzig, Marburg, München, Münster
2024-10-02
By invitation
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency
Glycomine, Inc.
Phase 2
90
Münster
2024-09-30
Recruiting
Janssen Research & Development, LLC
Phase 2/3
274
Bonn, Göttingen, Hanover, Leipzig, Ludwigshafen am Rhein, Münster, Tübingen
2024-09-19
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
Mannheim, Bonn, Düsseldorf, Münster, Kiel, Mainz
2024-09-11
Active, closed
GCP-Service International West GmbH
Phase 2
41
Düsseldorf, Leipzig, Münster
2024-09-10
Recruiting
Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease
NCT06523608Liver Diseases, Hepatocellular Carcinoma, Hepatocarcinoma, Advanced Chronic Liver Disease
University Hospital Muenster
Observational
600
Münster
2024-09-01
Recruiting
Alimera Sciences
Phase 4
25
Berlin, Münster
2024-08-31
Recruiting
Dr. Inge Winter
Phase 3
418
Bielefeld, Dortmund, Frankfurt am Main, Münster
2024-08-31
Recruiting
Prevail Therapeutics
Phase 1
124
Düsseldorf, Münster
2024-08-27
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Cologne, Frankfurt, Gauting, Großhansdorf, Hamburg, Heidelberg, Mainz, Münster
2024-08-22
Recruiting
Sanofi
Phase 3
160
Berlin, Bochum, Bremen, Essen, Göttingen, Hanover, Homburg, Münster
2024-08-21
Recruiting
AbbVie
Phase 3
675
Erlangen, Bad Bentheim, Münster, Dresden, Berlin
2024-08-19
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Tübingen, Cologne, Münster, Berlin
2024-08-16
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
Frankfurt, Hanover, München, Münster
2024-08-07
Recruiting
Dr. Inge Winter
Phase 4
418
Augsburg, Bielefeld, Dortmund, Frankfurt am Main, Mainz, Münster
2024-08-01
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
982
Essen, Bottrop, Dresden, Leipzig, Mönchengladbach, München, Münster, Wolfsburg
2024-07-31
Active, closed
Annexon, Inc.
Phase 3
659
Neubrandenburg, Münster, Bonn, Heidelberg, Tübingen
2024-07-30
Recruiting
Universität Münster
Observational
257
Münster
2024-07-24
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Aachen, Cologne, Homburg, Münster
2024-07-22
Recruiting
AO Innovation Translation Center
Observational
76
Freiburg im Breisgau, Münster
2024-07-10
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
136
Bad Saarow, Berlin, Dresden, Hamburg, Mannheim, München, Münster, Ulm
2024-07-09
Recruiting
AO Innovation Translation Center
Observational
600
Frankfurt, Giessen, Heidelberg, Münster, Wildeshausen
2024-07-03
Recruiting
Semibranch Registry - Retrospective
NCT06374355Aortic Aneurysm, Endovascular Aortic Repair, Stent-Graft Endoleak
University Hospital Muenster
Observational
100
Münster
2024-07-02
Recruiting
European Foundation for Study of Chronic Liver Failure
Phase 2
90
Aachen, Münster
2024-07-01
Recruiting
Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation
NCT07777744Ventricular Tachycardia (VT), Premature Ventricular Complexes
University Hospital, Basel, Switzerland
Observational
15,000
Bad Berka, Bad Krozingen, Cottbus, Münster
2024-07-01
Recruiting
Non Interventional German Leptomeningeal Disease Register
NCT06146010Meningeal Neoplasms, Leptomeningeal Disease
University Hospital Tuebingen
Observational
50
Bonn, Mannheim, München, Münster, Siegen, Tübingen, Ulm
2024-06-26
Recruiting
University Hospital Muenster
Not applicable
200
Münster
2024-06-20
Recruiting
ABX advanced biochemical compounds GmbH
Phase 3
380
Dresden, Düsseldorf, Gronau, Hamburg, Leipzig, München, Münster, Rostock
2024-06-13
Active, closed
Amgen
Phase 3
563
Cologne, Dresden, Essen, Gauting, Großhansdorf, Heidelberg, Münster, Würzburg
2024-06-05
Recruiting
Lohmann & Rauscher
Observational
110
Berlin, Mannheim, Munich, Münster, Rheine, Tübingen
2024-06-03
Active, closed
Stealth BioTherapeutics Inc.
Phase 3
313
Münster, Regensburg, Tübingen
2024-05-30
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Chemnitz, Frankfurt, Freiburg im Breisgau, Hanover, Homburg, Münster
2024-05-24
Recruiting
Baroloop Multicenter Trial (Baroloop MCT)
NCT06518915Hypertension, Resistant to Conventional Therapy
neuroloop GmbH
Not applicable
120
Münster, Mainz, Dresden
2024-05-22
Active, closed
Sanofi
Phase 3
1,541
Augsburg, Bad Bentheim, Hamburg, Kiel, Mainz, Münster, Witten
2024-05-08
Recruiting
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
DrugsMB-CART19.1·Zamtocabtagene autoleucel
Miltenyi Biomedicine GmbH
Not applicable
40
Berlin, Cologne, Erlangen, Göttingen, Münster, Tübingen, Würzburg
2024-05-05
By invitation
Travere Therapeutics, Inc.
Phase 3
100
Hamburg, Leipzig, Münster
2024-04-30
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 1/2
112
Berlin, Cologne, Freiburg im Breisgau, Greifswald, Halle, Kiel, Münster, Stuttgart
2024-04-15
Active, closed
Celldex Therapeutics
Phase 2
140
Augsburg, Bad Bentheim, Berlin, Bochum, Erlangen, Frankfurt, Heidelberg, Münster
2024-04-12
Recruiting
Daiichi Sankyo
Phase 1/2
680
Heidelberg, Heilbronn, Münster, Mainz, Dresden, Leipzig, Berlin
2024-04-10
Recruiting
Marc Bosiers, MD
Observational
109
Berlin, Frankfurt, Göttingen, Heidelberg, Lünen, Münster, Regensburg, Stuttgart
2024-04-05
Recruiting
University Hospital Goettingen
Phase 3
102
Heidelberg, München, Hamburg, Frankfurt am Main, Göttingen, Cologne, Münster, Leipzig
2024-03-25
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Chemnitz, Frankfurt am Main, Freiburg im Breisgau, Hanover, Homburg, Münster
2024-03-13
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Munich, Cologne, Aachen, Augsburg, Berlin, Essen, Münster, Rostock
2024-03-12
Recruiting
Edward Geissler
Phase 4
300
Aachen, Berlin, Dresden, Hamburg, Hanover, Jena, Mainz, Münster
2024-03-09
Recruiting
University Hospital Muenster
Observational
2,000
Chemnitz, Aachen, Greifswald, Leipzig, Münster, Tübingen
2024-03-01
Active, closed
Safety and Performance of the Biphasic Plate Distal Femur: A Multicenter Case Series
NCT06028971Distal Femur Fracture, Periprosthetic Fractures, Intra-Articular Fractures, Supracondylar Fracture
41medical AG
Observational
60
Münster, Siegen
2024-02-29
Recruiting
Aleksander Krag
Phase 3
240
Berlin, Jena, Münster
2024-02-26
Active, closed
Novo Nordisk A/S
Phase 2
88
Heidelberg, München, Münster, Würzburg
2024-02-20
Recruiting
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
NCT06279793Intensive Care Unit, Coronary Artery Bypass Grafting (CABG), High Risk Patients, Cardiopulmonary Bypass
GCP-Service International West GmbH
Phase 2
550
Augsburg, Berlin, Bonn, Göttingen, Hamburg, Kiel, Mainz, Münster
2024-02-15
Active, closed
Astellas Gene Therapies
Not applicable
119
Bonn, Essen, Höchheim, Münster
2024-02-01
Recruiting
CarThera
Phase 3
560
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2024-01-29
Active, closed
Sanofi
Phase 3
260
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Kiel, Münster, Regensburg
2024-01-23
Active, closed
Pfizer
Phase 3
394
Stuttgart, Bad Bentheim, Münster
2024-01-19
Recruiting
Universität Münster
Observational
50
Münster
2024-01-18
Recruiting
Outcome of the Semibranch in Pararenal and Thoracoabdominal Aortic Pathologies. A Prospective, Multicentre Registry.
NCT06059053Aortic Aneurysm, Endovascular Aortic Repair, Stent-Graft Endoleak
University Hospital Muenster
Observational
100
Münster
2024-01-12
Active, closed
Evangelical Hospital Düsseldorf
Observational
1,000
Düsseldorf, Hamburg, Karlsruhe, Münster
2024-01-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Munich, Schwerin, Bonn, Münster, Lübeck, Jena, Berlin, Hamburg
2023-12-31
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Münster, Homburg, Leipzig, Berlin, Essen
2023-12-29
Recruiting
Travere Therapeutics, Inc.
Phase 3
70
Hamburg, Leipzig, Münster
2023-12-28
Active, closed
AbbVie
Phase 3
614
Erlangen, Munich, Blankenfelde-Mahlow, Bonn, Frankfurt am Main, Bad Bentheim, Münster, Mainz
2023-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
München, Nuremberg, Marburg, Hanover, Moers, Münster, Mainz, Großhansdorf
2023-12-15
Recruiting
AbbVie
Phase 3
110
Munich, Münster
2023-12-11
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Göttingen, Stade, Dresden, Berlin, Mainz, Münster, Tübingen
2023-12-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Esslingen am Neckar, Gauting, Kempten (Allgäu), Regensburg, Bochum, Münster, Paderborn, Großhansdorf
2023-12-06
Recruiting
The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study
NCT05847387Corneal Transplant Failure, Corneal Endothelial Cell Loss
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Observational
135
Cologne, Münster
2023-12-01
Active, closed
Incyte Corporation
Phase 3
450
Bad Bentheim, Berlin, Dresden, Hamburg, Mahlow, Münster
2023-11-27
Recruiting
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
NCT05658640Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsTrametinib·Cytarabine·Dexamethasone·Cyclophosphamide
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2023-11-14
Recruiting
Takeda
Phase 3
80
Würzburg, Münster, Jena, Hamburg, Hanover
2023-11-13
Active, closed
AstraZeneca
Phase 3
314
Freiburg im Breisgau, Mainz, Minden, Münster, Tübingen
2023-11-08
Active, closed
AbbVie
Phase 3
122
Munich, Münster, Leipzig, Berlin
2023-11-06
Active, closed
Bristol-Myers Squibb
Phase 3
402
Erding, Münster, Koblenz, Leipzig, Jena, Berlin, Düsseldorf, Lübeck
2023-10-24
Recruiting
W.L.Gore & Associates
Not applicable
244
Bad Krozingen, Münster, Regensburg, Stuttgart
2023-10-17
Recruiting
AbbVie
Phase 3
1,500
Munich, Bad Bentheim, Düsseldorf, Münster, Lübeck, Berlin
2023-10-11
Recruiting
Fracture Monitor - Femur
NCT05410587Femoral Fracture
AO Innovation Translation Center
Not applicable
37
Homburg, Münster, Tübingen, Ulm
2023-10-03
By invitation
Biogen
Phase 3
306
Erlangen, Bad Bentheim, Oldenburg, Münster, Dresden, Halle, Berlin
2023-10-03
Recruiting
Universität Münster
Not applicable
165
Münster, Tübingen
2023-10-02
Active, closed
Universität Münster
Observational
60
Berlin, Cologne, Hamburg, Hanover, Mainz, Müllheim, Münster, Würzburg
2023-10-01
Active, closed
PharmaMar
Phase 3
469
München, Bad Saarow, Dresden, Hanover, Heidelberg, Manheim, Münster, Tübingen
2023-09-21
Recruiting
Jena University Hospital
Observational
100
Freiburg im Breisgau, Ulm, Münster, Halle, Jena
2023-09-05
Active, closed
Novartis Pharmaceuticals
Phase 2
144
Berlin, Bochum, Münster, Ulm
2023-08-25
Recruiting
Universität Münster
Observational
40
Berlin, Münster
2023-08-24
Active, closed
The BD Liverty™ TIPS Stent Graft Study
NCT05711316Portal Hypertension, TIPS
C. R. Bard
Not applicable
177
Berlin, Bonn, Dresden, Frankfurt, Hanover, Münster
2023-08-08
Recruiting
Amicus Therapeutics
Phase 3
36
Giessen, Heidelberg, Höchheim, Münster
2023-07-18
Active, closed
Zenith Thoracic Alpha (ZTA) Post-Market Data Collection
NCT06094127Thoracic Aortic Aneurysm, Penetrating Aortic Ulcer
Cook Research Incorporated
Observational
300
Hamburg, München, Münster
2023-07-06
Active, closed
Viatris Innovation GmbH
Phase 3
451
Frankfurt am Main, Leipzig, Minden, Münster
2023-06-26
Active, closed
Alfasigma S.p.A.
Observational
509
Grünwald, Amberg, Dachau, Hamburg, Heidelberg, Kiel, Leipzig, Münster
2023-06-12
Recruiting
European Aortic Data Collection Project
NCT05896397Complex Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm, Chronic Aortic Dissection
Cook Research Incorporated
Observational
600
Hamburg, Munich, Münster, Nuremberg
2023-05-31
Recruiting
Pfizer
Phase 2
100
Freiburg im Breisgau, Ulm, Würzburg, Frankfurt am Main, Hanover, Essen, Münster, Kiel
2023-05-17
Recruiting
Remote Ischemic Preconditioning in Septic Patients
NCT05830669Critically Ill, Acute Kidney Injury, Sepsis
Universität Münster
Not applicable
64
Münster
2023-05-11
Recruiting
Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
NCT06954636Glioblastoma Multiforme, Adult, Glioblastoma or Gliosarcoma, Glioblastoma, Adult
Sied Kebir
Observational
128
Essen, Münster
2023-05-03
Active, closed
Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study
NCT05639569Aneurysm Thoracic, Dissection of Thoracic Aorta
Lifetech Scientific (Shenzhen) Co., Ltd.
Observational
147
Hamburg, Münster
2023-05-03
Recruiting
Improving Low ASPECTS Stroke Thrombectomy
NCT04862507Acute Ischemic Stroke
Universitätsklinikum Hamburg-Eppendorf
Observational
500
Berlin, Bremen, Hamburg, Kaiserslautern, Marburg, Münster, Rostock
2023-05-01
Active, closed
Sanofi
Phase 2
999
Augsburg, Bad Bentheim, Berlin, Dresden, Münster, Osnabrück, Rostock, Witten
2023-04-03
Active, closed
PerQseal® Clinical Study
NCT05653336Percutaneous Large Hole Vascular Closure
Vivasure Medical Limited
Not applicable
149
Münster, Leipzig, Berlin
2023-03-30
Active, closed
Boston Scientific Corporation
Observational
1,173
Aachen, Dresden, Göttingen, Hamburg, Heidelberg, Karlsruhe, Münster
2023-03-24
Active, closed
University Hospital Muenster
Not applicable
480
Münster
2023-03-22
By invitation
Eli Lilly and Company
Phase 3
333
Darmstadt, Frankfurt am Main, Bad Bentheim, Münster, Dresden
2023-03-09
Recruiting
Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment
NCT07674173Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft
Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd
Observational
200
Immenstadt im Allgäu, Münster
2023-03-05
Recruiting
Filter Lifespan in Continuous Renal Replacement Therapy
NCT05450185Critically Ill, Continuous Renal Replacement Therapy, Infections
University Hospital Muenster
Observational
600
Erlangen, Mönchengladbach, Münster
2023-03-02
Recruiting
Eli Lilly and Company
Phase 3
595
Bad Bentheim, Berlin, Dresden, Frankfurt am Main, Hamburg, Mainz, München, Münster
2023-02-27
Active, closed
VIATORR Device Registry
NCT05661331Chronic Liver Disease
W.L.Gore & Associates
Observational
196
Freiburg im Breisgau, Münster
2023-02-21
Recruiting
Outcome of a Triple Inner Branched Aortic Arch Stentgraft. A Prospective, Multicenter Registry.
NCT05530304Aortic Arch, Aortic Arch Aneurysm, Dissection of Aortic Arch, Triple Branch
University Hospital Muenster
Observational
30
Münster
2023-02-09
Recruiting
University Hospital Tuebingen
Not applicable
144
Frankfurt a.M., Cologne, Münster, Tübingen
2023-02-06
Recruiting
University Hopsital Schleswig Holstein Campus Lübeck
Phase 2/3
100
Berlin, Bielefeld, Hamburg, Lübeck, Münster, Würzburg
2023-02-03
By invitation
University Hospital Muenster
Not applicable
25
Münster
2023-02-02
Recruiting
Tenaya Therapeutics
Observational
200
Münster, Würzburg
2023-01-31
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Augsburg, Cologne, Essen, Frankfurt, Leipzig, Munich, Münster
2023-01-05
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2022-12-13
Active, closed
Celcuity Inc
Phase 3
701
Bayreuth, Berlin, Dorf Mecklenburg, Lübeck, Mainz, Münster, Saarbrücken, Wuppertal
2022-12-08
By invitation
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Cologne, Heidelberg, Homburg, Münster, Würzburg
2022-11-30
Recruiting
Hoffmann-La Roche
Phase 1/2
65
Münster
2022-11-16
Recruiting
Universität Münster
Phase 1/2
34
Münster
2022-11-09
Recruiting
Bayer
Phase 3
100
Heidelberg, Hanover, Bonn, Essen, Münster, Berlin, Hamburg
2022-11-08
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Bad Mergentheim, Elsterwerda, Essen, Hamburg, Leipzig, Münster, Stuttgart, Wangen
2022-11-01
Recruiting
Regeneron Pharmaceuticals
Observational
500
Konstanz, Weinsberg, München, Nuremberg, Georgsmarienhütte, Rotenburg (Wümme), Münster, Troisdorf
2022-10-26
Active, closed
Eli Lilly and Company
Phase 3
377
Bad Bentheim, Darmstadt, Dresden, Frankfurt, Münster
2022-10-18
Active, closed
Genmab
Phase 1
17
Erlangen, Marburg, Münster
2022-10-04
Recruiting
PedAL BCU, LLC
Phase 3
130
Augsburg, Berlin, Frankfurt, Münster
2022-10-01
Active, closed
VisionCare, Inc.
Not applicable
68
Karlsruhe, Münster
2022-09-13
Recruiting
Acrivon Therapeutics
Phase 2
350
Essen, Münster, Ulm
2022-08-29
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 2
256
Muenchen, Halle, Essen, Frankfurt, Mönchengladbach, Münster, Tübingen
2022-08-17
Recruiting
Bristol-Myers Squibb
Observational
1,700
Aalen, Erlangen, Münster, Dresden, Leipzig, Bernau, Berlin
2022-08-16
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Berlin, Georgsmarienhütte, Giessen, Münster, Recklinghausen, Weinsberg
2022-08-05
Active, closed
AstraZeneca
Phase 3
341
Berlin, Chemnitz, Frankfurt A. Main, Gauting, Immenhausen, Löwenstein, München, Münster
2022-08-03
Recruiting
IntraBio Inc
Phase 3
53
Giessen, Hamburg, Höchheim, München, Münster
2022-06-30
Active, closed
Camurus AB
Phase 2/3
71
Hanover, Leipzig, Münster
2022-06-28
Active, closed
SIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries
NCT04971772Peripheral Arterial Disease, Superficial Femoral Artery Stenosis, Angiopathy, Peripheral
Cardionovum GmbH
Observational
150
Berlin, Alsfeld, Hamburg, Heidelberg, Karlsruhe, Münster, Weinheim
2022-06-08
Recruiting
BioMarin Pharmaceutical
Observational
450
Cottbus, Hamburg, Leipzig, Mainz, Münster, Ulm
2022-06-06
Active, closed
Genentech, Inc.
Observational
400
Bonn, Freiburg im Breisgau, Göttingen, Hanover, Leipzig, Münster, Tübingen
2022-05-27
Recruiting
TolerogenixX GmbH
Phase 2
126
Berlin, Hamburg, Heidelberg, Munich, Münster, Stuttgart
2022-05-04
By invitation
AstraZeneca
Phase 3
214
Gütersloh, Münster, Oldenburg
2022-04-19
Active, closed
Janssen Research & Development, LLC
Phase 1/2
235
Dresden, Duisburg, Frankfurt am Main, Herne, Mettmann, Münster, Ulm
2022-04-11
Active, closed
Bayer
Phase 3
219
Heidelberg, Hanover, Bonn, Essen, Münster, Berlin, Hamburg
2022-03-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Singen, Tübingen, Munich, Aachen, Bonn, Düsseldorf, Essen, Münster
2022-03-15
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Münster, Manheim, Mannheim, Augsburg, Berlin, Hamburg, München, Ulm
2022-03-07
Recruiting
Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
Observational
300
Berlin, Dessau, Hamburg, Leipzig, Marburg, Münster, Rotenburg (Wümme)
2022-02-28
Recruiting
Sanofi
Phase 3
284
Bad Bentheim, Berlin, Frankfurt, Mainz, Münster
2022-02-15
Active, closed
UCB Biopharma SRL
Phase 3
113
Göttingen, Münster
2022-02-02
Active, closed
Microvention-Terumo, Inc.
Observational
206
Augsburg, Bochum, Essen, Münster
2022-01-14
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Freiburg im Breisgau, Ulm, Bonn, Münster, Ludwigshafen am Rhein, Hamburg, Püttlingen
2022-01-13
Active, closed
Immunic AG
Phase 3
1,100
Münster
2022-01-12
Active, closed
Eli Lilly and Company
Phase 3
152
Heidelberg, Löwenstein, Gauting, München, Immenhausen, Georgsmarienhütte, Hanover, Münster
2021-12-20
Active, closed
Regeneron Pharmaceuticals
Phase 3
288
München, Essen, Münster, Leipzig, Berlin, Jena
2021-12-14
Recruiting
JOTEC GmbH
Observational
500
Münster
2021-12-06
Active, closed
Immunic AG
Phase 3
1,121
Münster
2021-11-18
Recruiting
Insel Gruppe AG, University Hospital Bern
Phase 3
70
Freiburg im Breisgau, München, Düsseldorf, Münster, Berlin, Hanover
2021-11-16
Active, closed
University of Leipzig
Not applicable
262
Coburg, Giessen, Münster, Dresden, Berlin, Leipzig
2021-11-12
Recruiting
A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses
NCT06839898Myopia, Moderate, Myopic Astigmatism, Myopia, Degenerative
Biotech Healthcare Holding Gmbh
Not applicable
172
Münster, Rheine, Steinfurt
2021-10-10
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Chemnitz, Frankfurt, Hanover, Kiel, Leipzig, Magdeburg, Münster, Tübingen
2021-09-22
Recruiting
medac GmbH
Phase 3
210
Munich, Würzburg, Frankfurt am Main, Hanover, Cologne, Essen, Münster, Dresden
2021-08-16
Active, closed
Regeneron Pharmaceuticals
Observational
717
Mannheim, Berlin, Hennigsdorf, Wiesbaden, Düsseldorf, Münster, Dresden, Jena
2021-08-12
Active, closed
Hoffmann-La Roche
Phase 1
119
Dresden, Göttingen, München, Münster, Tübingen, Ulm
2021-08-11
Active, closed
Biotronik AG
Observational
160
Bayreuth, Essen, Flensburg, Jena, Münster, Tübingen
2021-08-10
Active, closed
AbbVie
Phase 3
132
Bad Bentheim, Bonn, Münster, Mainz, Dresden, Kiel
2021-07-24
Active, closed
Biogen
Phase 3
562
Göttingen, Hanover, Cologne, Münster, Mainz
2021-07-16
Active, closed
Hoffmann-La Roche
Phase 3
451
Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster
2021-07-14
Active, closed
VectivBio AG
Phase 3
158
Berlin, Bonn, Hamburg, Heidelberg, Münster
2021-07-13
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Würzburg, Cologne, Essen, München, Münster, Rostock
2021-06-09
Active, closed
Sanofi
Phase 2
129
Leipzig, Münster
2021-06-07
Recruiting
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
NCT04503395Aortic Aneurysm, Abdominal
FCRE (Foundation for Cardiovascular Research and Education)
Not applicable
204
Aachen, Leipzig, München, Münster
2021-05-21
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Berlin, Düsseldorf, Giessen, Hanover, Kiel, München, Münster, Regensburg
2021-04-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Freiburg im Breisgau, Tübingen, Regensburg, Würzburg, Herne, Münster, Dresden, Halle
2021-04-21
Recruiting
King's College Hospital NHS Trust
Phase 3
210
Bonn, Hamburg, Ludwigshafen, München, Münster, Sulzbach, Ulm, Würzburg
2021-04-16
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Ulm, Würzburg, Giessen, Münster, Koblenz, Mainz, Lübeck, Hamburg
2021-04-08
Recruiting
Bristol-Myers Squibb
Phase 3
153
Münster, Mainz, Dresden, Berlin, Hamburg
2021-03-23
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Dresden, Jena, Leipzig, Mainz, Münster, Regensburg
2021-03-04
Recruiting
CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1
NCT04455282Cancer of Esophagus, Esophagogastric Junction Disorder
Heinrich-Heine University, Duesseldorf
Observational
100
Cologne, Münster
2021-02-01
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Berlin, Heidelberg, Münster, Würzburg
2021-02-01
Active, closed
AstraZeneca
Phase 3
1,371
Berlin, Dessau-RoBlau, Essen, Freiburg im Breisgau, Mönchengladbach, München, Münster, Regensburg
2021-01-28
Active, closed
Janssen Research & Development, LLC
Phase 2
220
Cologne, Duisburg, Herne, Markkleeberg, Mettmann, Münster, Nuremberg, Nürtingen
2020-12-18
Active, closed
Universität Münster
Phase 2
190
Münster, Augsburg, Bergisch Gladbach, Cologne, Duisburg, Düsseldorf, Essen, Frankfurt
2020-12-10
Active, closed
Hoffmann-La Roche
Phase 3
769
Dresden, Greifswald, Hanover, Leipzig, Münster, Tübingen, Ulm, Wiesbaden
2020-12-03
Active, closed
Science Corporation
Not applicable
38
Aachen, Bonn, Hamburg, Ludwigshafen am Rhein, Lübeck, Munich, Münster, Sulzbach
2020-11-24
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 3
691
Berlin, Braunschweig, Dresden, Essen, München, Münster
2020-11-12
Active, closed
Bayer
Phase 4
654
Münster, Mainz
2020-11-09
Recruiting
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
NCT04588311Trauma, Traumatic Injury, Traumatic Brain Injury, Wounds and Injuries
DrugEpoetin Alfa
Australian and New Zealand Intensive Care Research Centre
Phase 3
2,500
Münster
2020-11-09
Active, closed
Exelixis
Phase 3
575
Nürtingen, Duisburg, Gütersloh, Münster, Lübeck, Berlin, Hamburg, Hanover
2020-10-19
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Braunschweig, Cologne, Dresden, Duisburg, Hanover, München, Münster, Nürtingen
2020-09-23
Active, closed
BGP+ Stent as Bridging Stent in BEVAR
NCT03982940Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture
Marc Bosiers, MD
Not applicable
118
Heidelberg, Kiel, Aachen, Hamburg, Leipzig, Munich, Münster, Nuremberg
2020-09-09
Active, closed
Philogen S.p.A.
Phase 2
98
Münster, Bad Saarow, Berlin, München
2020-08-28
Active, closed
Combination of Ranibizumab and Targeted Laser Photocoagulation
NCT04444492Central Retinal Vein Occlusion With Macular Edema
DrugsLucentis·Ranibizumab
University of Giessen
Phase 3
88
Freiburg im Breisgau, Giessen, Hanover, Leipzig, Ludwigshafen, Marburg, München, Münster
2020-08-25
Recruiting
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
NCT05040373Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy
Alnylam Pharmaceuticals
Observational
10
Münster
2020-08-01
Active, closed
STABILITY 2: Anterior Cruciate Ligament Reconstruction +/- Lateral Tenodesis With Patellar vs Quad Tendon
NCT03935750Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Joint Instability
University of Pittsburgh
Not applicable
1,272
Cologne, Münster
2020-07-28
Active, closed
AstraZeneca
Phase 3
866
Berlin, Dresden, Freiburg im Breisgau, Hanover, München, Münster, Velbert
2020-07-24
Active, closed
GlaxoSmithKline
Phase 3
242
Erlangen, Münster
2020-07-14
Active, closed
AstraZeneca
Phase 3
1,012
Berlin, Duisburg, Hamburg, Herne, Mettmann, Münster, Nuremberg, Nürtingen
2020-07-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Göttingen, Minden, Münster, Neuss, Großhansdorf, Bad Berka, Jena, Berlin
2020-07-06
Recruiting
Amgen
Phase 1
479
Essen, Heidelberg, München, Münster
2020-03-04
By invitation
RegisterPROS - A Registry for Prostate Cancers
NCT06872619Prostate Cancer (Adenocarcinoma), Prostate Biopsy, Prostatectomy, Radioligand
Wren Laboratories LLC
Observational
1,000
Münster
2020-01-15
Active, closed
Pfizer
Phase 3
1,068
Duisburg, Frankfurt, Münster, Nürtingen, Tübingen
2019-12-30
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Vascutek Ltd.
Observational
1,000
Augsburg, Berlin, Chemnitz, Freiburg im Breisgau, Göttingen, Lingen, Münster, Tübingen
2019-12-17
Recruiting
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
Abbott Medical Devices
Observational
1,000
Tübingen, Düsseldorf, Münster, Mainz, Homburg, Hamburg
2019-11-26
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
Frankfurt am Main, Leipzig, Essen, Göttingen, Heidelberg, Münster, Würzburg
2019-11-26
Active, closed
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
NCT04232241Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
Universitätsklinikum Hamburg-Eppendorf
Phase 2
167
Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg, Hanover, Leipzig, Münster
2019-11-14
Active, closed
AbbVie
Phase 1/2
218
Ulm, Münster, Leipzig
2019-11-06
Active, closed
TME Pharma AG
Phase 1/2
117
Bonn, Essen, Leipzig, Mannheim, Münster, Tübingen
2019-09-12
Active, closed
Christian Buske
Phase 2
53
Bielefeld, Bremen, Halle, Mannheim, Mönchengladbach, Mutlangen, München, Münster
2019-09-11
Active, closed
Exelixis
Phase 3
855
Heidelberg, Tübingen, Frankfurt am Main, Münster, Mainz, Jena, Dresden
2019-06-25
Active, closed
AbbVie
Phase 1/2
220
Cologne, Münster, Dresden, Hamburg
2019-06-24
Active, closed
LEO Pharma
Phase 2
131
Bad Bentheim, Berlin, Bonn, Erlangen, Frankfurt am Main, München, Münster, Oldenburg
2019-05-29
Active, closed
Novo Nordisk A/S
Phase 3
1,500
Friedrichsthal, Hamburg, Münster, Rehlingen-Siersburg, Saint Ingbert-Oberwürzbach
2019-05-08
Active, closed
PROSpect: Prone and Oscillation Pediatric Clinical Trial
NCT03896763Acute Respiratory Distress Syndrome in Children
University of Pennsylvania
Not applicable
600
Münster
2019-05-01
Active, closed
Fracture-Related Outcome Study for Operatively Treated Tibia Shaft Fractures
NCT03598530Tibial Fracture, Fracture of the Tibia Type AO/OTA 42
AO Clinical Investigation and Publishing Documentation
Observational
1,000
Mainz, Munich, Münster
2019-04-04
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
DrugsZanzalintinib·Avelumab·Tecentriq·Atezolizumab
Exelixis
Phase 1
325
Nürtingen, Münster, Hamburg
2019-03-20
Active, closed
Xenon Pharmaceuticals Inc.
Phase 2
325
Berlin, Bielefeld, Bonn, Frankfurt, Freiburg im Breisgau, Münster, Osnabrück, Regensburg
2019-01-30
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Braunschweig, Duisburg, Homburg, Magdeburg, Münster, Nürtingen
2019-01-25
Recruiting
Periprosthetic Fracture Registry (PPFx)
NCT03378557Periprosthetic Fractures, Periprosthetic Fracture Around Prosthetic Joint Implant
AO Innovation Translation Center
Observational
600
Berlin, Ludwigshafen, Münster
2018-12-31
Active, closed
W.L.Gore & Associates
Observational
280
Heidelberg, Münster
2018-12-18
Active, closed
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
NCT03853616Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent
DrugMB-CART19.1
Miltenyi Biomedicine GmbH
Phase 1
48
Berlin, Erlangen, Göttingen, Munich, Münster, Tübingen, Würzburg
2018-11-26
Active, closed
Eli Lilly and Company
Phase 2/3
393
Nürtingen, Tübingen, Holzminden, Cologne, Mettmann, Münster, Wesel, Leipzig
2018-11-26
Active, closed
IRCCS San Raffaele
Observational
200
Nuremberg, Hamburg, Münster
2018-10-30
Active, closed
Tesaro, Inc.
Phase 3
1,400
Berlin, Hamburg, Kiel, Münster, Ravensburg, Wolfsburg
2018-10-11
Active, closed
AstraZeneca
Phase 3
730
Berlin, Cologne, Freiburg im Breisgau, Gauting, Heidelberg, Mainz, Münster, Oldenburg
2018-09-27
Recruiting
Hoffmann-La Roche
Phase 3
1,000
Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster
2018-09-20
Active, closed
AbbVie
Phase 3
1,533
Heidelberg, Frankfurt am Main, Münster, Selters, Kiel, Bonn, Hamburg, Hanover
2018-08-09
Active, closed
Rna Diagnostics Inc.
Not applicable
801
Münster
2018-04-26
Active, closed
Merck Sharp & Dohme LLC
Phase 2
340
Munich, Giessen, Essen, Münster, Berlin
2018-04-09
Active, closed
Development of Novel Clinical Endpoints in Intermediate AMD
NCT03349801Age Related Macular Degeneration (AMD)
Frank G. Holz
Observational
718
Bonn, Cologne, Freiburg im Breisgau, Munich, Münster, Tübingen, Ulm
2018-03-26
Active, closed
Heinrich-Heine University, Duesseldorf
Phase 2
136
Bochum, Duisburg, Düsseldorf, Lünen, Münster, Krefeld
2018-03-06
Active, closed
Pfizer
Phase 3
1,054
Düsseldorf, Hamburg, Heidelberg, Kirchheim, Münster, Nürtingen
2017-12-18
Recruiting
Registry for Patients With Lipodystrophy
NCT03553420Lipodystrophy Acquired, Lipodystrophy Congenital
University of Ulm
Observational
5,000
Hanover, Leipzig, Münster, Ulm
2017-12-16
Active, closed
BioMarin Pharmaceutical
Phase 3
119
Magdeburg, Münster
2017-12-12
Active, closed
Endurant CHevAr New Indication Trial: ENCHANT
NCT03320252AAA - Abdominal Aortic Aneurysm
Medtronic Cardiovascular
Observational
150
Chemnitz, Essen, Frankfurt am Main, Heidelberg, Münster
2017-10-26
Recruiting
Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases
NCT04706234Multiple System Atrophy, Parkinson Disease, Progressive Supranuclear Palsy, Motor Neuron Disease
Kliniken Beelitz GmbH
Observational
350
Ulm, Beelitz-Heilstätten, Hanover, Münster, Dresden, Stadtroda, Hamburg
2017-09-01
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
518
Bottrop, Cologne, Essen, Frankfurt, Hanover, Kiel, Münster, Schweinfurt
2017-06-21
Active, closed
Acerta Pharma BV
Phase 3
635
Heidelberg, München, Münster, Nordrhein-Westfalen, Ravensburg, Rheinland-Pfalz, Ulm
2017-04-05
Active, closed
European Association of Urology Research Foundation
Observational
1,054
Hamburg, Mainz, Münster
2017-02-22
Active, closed
AbbVie
Phase 3
443
Ulm, Frankfurt am Main, Münster, Halle, Hamburg, Hanover
2017-02-02
Recruiting
University College, London
Observational
2,500
Ulm, Dresden, Bochum, Erlangen, Münster, Taufkirchen
2017-01-01
Recruiting
Prospective Validation Study of the CD8+TEMRA Cells As a Prognostic Biomarker of Healing Outcome After Fracture
NCT06658379Fracture Non Union, Fracture Healing, Long Bone Delayed-Union Fracture, Humerus Shaft Fracture
Charite University, Berlin, Germany
Observational
640
Münster, Dresden, Leipzig, Berlin, Eisenberg
2016-12
Active, closed
Eisai Inc.
Phase 3
1,069
Stuttgart, Tübingen, München, Frankfurt am Main, Hanover, Greifswald, Münster, Homburg/Saar
2016-10-13
Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT02325674Generalised Lipodystrophy, Partial Lipodystrophy
DrugMetreleptin
Chiesi Farmaceutici S.p.A.
Observational
100
Ulm, Hanover, Münster, Leipzig
2016-10-11
Recruiting
Suphi Taneri
Observational
5,000
Münster
2016-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Braunschweig, Chemnitz, Dessau, Frankfurt, Gronau, Jena, Münster, Nürtingen
2015-11-19
Active, closed
AstraZeneca
Phase 3
1,126
Düsseldorf, Erlangen, Hanover, Heidelberg, Jena, München, Münster
2015-11-02
Active, closed
Regeneron Pharmaceuticals
Phase 3
880
Tübingen, Frankfurt am Main, Münster, Dresden, Gera, Hamburg, Munich, München
2015-10-15
Recruiting
Surgery for Recurrent Glioblastoma
NCT02394626Glioblastoma
Insel Gruppe AG, University Hospital Bern
Phase 2
120
Erfurt, Münster
2015-05-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Heidelberg, Münster, Nürtingen, Wuppertal
2014-11-26
Recruiting
International Primary Ciliary Dyskinesia (PCD) Registry
NCT02419365Primary Ciliary Dyskinesia (PCD)
University Hospital Muenster
Observational
2,000
Münster
2014-01
By invitation
Juvenile Inflammatory Rheumatism (JIR) Cohorte
NCT02377245Arthritis, Juvenile Rheumatoid
Michaël Hofer
Observational
15,000
Münster
2014-01
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Essen, Hanover, Heidelberg, Lübeck, Münster, Tübingen
2013-03-18
Active, closed
German Corneal Cross Linking Register
NCT00560651Keratoconus
Suphi Taneri
Observational
356
Homburg, Münster
2007-11
Recruiting
Exactech Shoulder Post Market Clinical Follow-up Study
NCT05603728Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy
Exactech
Observational
20,000
Erlangen, Münster
2007-07-19
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Berlin, Giessen, Münster, Würzburg
2001-07-31
Rows per page Showing 1–353 of 353
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 October 2026. https://priyalifescience.com/clinical-trials-germany/city/m-nster

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,060 studies in total at the last sync on 14 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 353 of those studies with a site in Münster.

How many clinical trials are recruiting in Münster?

185 of the 353 studies on this page are recruiting new participants as of the 14 Oct 2026, 03:18 UTC sync. A further 8 have not yet opened recruitment, 150 are active but closed to new participants, and 10 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Münster), 353 studies
PhaseStudiesRecruitingShare
Phase 31436140.5%
Observational795322.4%
Phase 2572816.1%
Not applicable35199.9%
Phase 1/216114.5%
Phase 11062.8%
Phase 2/3732%
Phase 4641.7%

Most active sponsors

Lead sponsors with the most studies (Münster)
Lead sponsorStudiesRecruiting
University Hospital Muenster1613
Universität Münster1410
AstraZeneca134
AbbVie124
Merck Sharp & Dohme LLC127
Novartis Pharmaceuticals127
Eli Lilly and Company94
Janssen Research & Development, LLC92
Pfizer95
Sanofi93
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.